Global Pharma companies in an effort to control R&D costs and increase efficiency are increasingly outsourcing their R&D projects. India with skilled workforce at a competitive cost stands to benefit from this trend. The Inflation Reduction Act should also help demand along with prevailing China +1 strategy. The R&D pipeline sees biologics/large molecules outpacing small molecules since FY18.